Wealthspire Advisors LLC Cuts Stock Holdings in AbbVie Inc. $ABBV

Wealthspire Advisors LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 5.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,854 shares of the company’s stock after selling 2,888 shares during the quarter. Wealthspire Advisors LLC’s holdings in AbbVie were worth $9,440,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Obermeyer Wealth Partners increased its position in shares of AbbVie by 2.7% during the 1st quarter. Obermeyer Wealth Partners now owns 23,809 shares of the company’s stock valued at $4,988,000 after purchasing an additional 617 shares during the last quarter. Ignite Planners LLC raised its holdings in shares of AbbVie by 9.5% during the 1st quarter. Ignite Planners LLC now owns 4,818 shares of the company’s stock valued at $931,000 after buying an additional 418 shares in the last quarter. Finally, PFG Advisors lifted its position in AbbVie by 17.8% in the 1st quarter. PFG Advisors now owns 26,341 shares of the company’s stock worth $5,519,000 after buying an additional 3,972 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on ABBV. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research note on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, Evercore ISI upped their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Trading Down 0.1%

Shares of ABBV opened at $233.83 on Wednesday. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The firm’s 50-day moving average price is $225.84 and its 200-day moving average price is $204.57. The firm has a market capitalization of $413.27 billion, a price-to-earnings ratio of 111.35, a PEG ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.